Talis Biomedical
In David Einhorn's portfolio · Greenlight Capital
Ticker TLIS
Not in the portfolio as of Q3 2026. Every quarter it shows up in a Greenlight Capital 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q3 2024 | Sell | 0 | |
| Q2 2024 | No change | 149,052 | 0.1% |
| Q1 2024 | No change | 149,052 | 0.1% |
| Q4 2023 | No change | 149,052 | 0.1% |
| Q3 2023 | No changeafter split | 149,052 | 0.0% |
| Q2 2023 | No change | 2,235,783 | 0.1% |
| Q1 2023 | No change | 2,235,783 | 0.1% |
| Q4 2022 | No change | 2,235,783 | 0.1% |
| Q3 2022 | No change | 2,235,783 | 0.1% |
| Q2 2022 | No change | 2,235,783 | 0.1% |
| Q1 2022 | Add 42% | 2,235,783 | 0.2% |
| Q4 2021 | Buy | 1,569,300 | 0.4% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.